CFTR and cystic fibrosis: Success with SMA primary DNA-based screening, however, has created interest in applying the same strategy for CF NBS when analytical biotechnology advances enough to enable fast, affordable complete CFTR analysis for CF-causing variants, as it inevitably will and perhaps not very far into the future.